Dimerix’ (ASX:DXB) CLARITY 2.0 study to obtain regulatory approval soon

ASX-listed clinical-stage drug developer Dimerix Limited (ASX:DXB) updated the market with the progress of CLARITY 2.0 study in COVID-19 patients.

Below are a few key highlights-

© Nastyazhi | Megapixl.com

  • DMX-200, a lead drug candidate of Dimerix, is a part of two different investigator-led Phase 3 clinical trials in patients having COVID-19 related respiratory complications.
  • CLARITY 2.0 study targeted at COVID-19 patients who are at an earlier stage of respiratory complications before the onset of ARDS.
  • The primary endpoint of the study is 7-point clinical health at day 14 of the treatment, adapted from the categorical scale.
  • Dimerix to start recruitment following the regulatory approval.
  • The Company disclosed that dossiers for regulatory approval have been submitted to regulatory authorities in India.

DETAILED DISCUSSION AT: Here’s why Dimerix (ASX:DXB) shares are moving north today

Comment


Disclaimer

Ad

GET A FREE STOCK REPORT


Top Penny Picks under 20 Cents to Fit Your Pocket! Get Exclusive Report on Penny Stocks For FREE Now.


   
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it. OK